Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2020 02:00 ET | Source: Verona Pharma plc

Update on AGM Procedure

LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
March 31, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation...
March 31, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation...
March 20, 2020 07:28 ET | Source: Verona Pharma plc

Verona Pharma plc: Issue of Equity and Total Voting Rights

LONDON, March 20, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
March 16, 2020 13:13 ET | Source: Verona Pharma plc

2019 Annual Report and Accounts and Notice of AGM

LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
March 05, 2020 11:01 ET | Source: Verona Pharma plc

Grant of Restricted Stock Units and PDMR Dealings

LONDON, March 05, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
February 27, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management changes Conference Call Today at 9:00 am EST / 2:00 pm GMT LONDON, Feb. 27, 2020 ...
February 21, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
February 14, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

LONDON, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
February 07, 2020 02:00 ET | Source: Verona Pharma plc

Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word...